160 related articles for article (PubMed ID: 10073330)
1. Effect of venlafaxine on the pharmacokinetics of risperidone.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
J Clin Pharmacol; 1999 Mar; 39(3):297-309. PubMed ID: 10073330
[TBL] [Abstract][Full Text] [Related]
2. Effect of venlafaxine on the pharmacokinetics of terfenadine.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
Psychopharmacol Bull; 1998; 34(3):383-9. PubMed ID: 9803772
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
4. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.
Kim KA; Park PW; Liu KH; Kim KB; Lee HJ; Shin JG; Park JY
J Clin Pharmacol; 2008 Jan; 48(1):66-72. PubMed ID: 18094221
[TBL] [Abstract][Full Text] [Related]
5. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
J Clin Pharmacol; 1999 Mar; 39(3):252-9. PubMed ID: 10073324
[TBL] [Abstract][Full Text] [Related]
6. Risperidone: effects of formulations on oral bioavailability.
Gutierrez R; Lee PI; Huang ML; Woestenborghs R
Pharmacotherapy; 1997; 17(3):599-605. PubMed ID: 9165565
[TBL] [Abstract][Full Text] [Related]
7. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.
Aravagiri M; Marder SR
Psychopharmacology (Berl); 2002 Feb; 159(4):424-31. PubMed ID: 11823895
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
Vermeulen A; Piotrovsky V; Ludwig EA
J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
[TBL] [Abstract][Full Text] [Related]
9. Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers.
Belotto KC; Raposo NR; Ferreira AS; Gattaz WF
Clin Ther; 2010 Nov; 32(12):2106-15. PubMed ID: 21118746
[TBL] [Abstract][Full Text] [Related]
10. [Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].
Ding JJ; Jiao Z; Yu YQ; Shi XJ
Yao Xue Xue Bao; 2007 Jun; 42(6):631-8. PubMed ID: 17702401
[TBL] [Abstract][Full Text] [Related]
11. Effect of venlafaxine on the pharmacokinetics of alprazolam.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
Psychopharmacol Bull; 1998; 34(2):211-9. PubMed ID: 9641003
[TBL] [Abstract][Full Text] [Related]
12. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.
Nakagami T; Yasui-Furukori N; Saito M; Tateishi T; Kaneo S
Clin Pharmacol Ther; 2005 Jul; 78(1):43-51. PubMed ID: 16003291
[TBL] [Abstract][Full Text] [Related]
13. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
Bork JA; Rogers T; Wedlund PJ; de Leon J
J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
[TBL] [Abstract][Full Text] [Related]
14. Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.
Lancelin F; Bourcier E; Le Masson V; Lemeille Y; Brovedani S; Paubel P; Piketty ML
Ther Drug Monit; 2010 Dec; 32(6):757-61. PubMed ID: 21068648
[TBL] [Abstract][Full Text] [Related]
15. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
Hendset M; Molden E; Refsum H; Hermann M
J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
[TBL] [Abstract][Full Text] [Related]
17. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
[TBL] [Abstract][Full Text] [Related]
18. Influence of age and gender on risperidone plasma concentrations.
Aichhorn W; Weiss U; Marksteiner J; Kemmler G; Walch T; Zernig G; Stelzig-Schoeler R; Stuppaeck C; Geretsegger C
J Psychopharmacol; 2005 Jul; 19(4):395-401. PubMed ID: 15982995
[TBL] [Abstract][Full Text] [Related]
19. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.
Hynninen VV; Olkkola KT; Bertilsson L; Kurkinen K; Neuvonen PJ; Laine K
Clin Pharmacol Ther; 2008 Feb; 83(2):342-8. PubMed ID: 17687273
[TBL] [Abstract][Full Text] [Related]
20. Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.
Duval F; Guillon MS; Mokrani MC; Crocq MA; Garcia Duarte F
Psychoneuroendocrinology; 2008 Feb; 33(2):255-9. PubMed ID: 18053652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
